A healthcare company in China looks for therapeutic assets in late clinical stages (after completion of Phase 2) for in-licensing rights for China market, and in preclinical stage for company formation, especially with cutting technology platforms. Preclinical in vivo data for early stage assets are critical.
In the life sciences, the firm is currently looking for innovative therapeutics companies. The firm will focus on assets in five indication areas: oncology, CNS, cardiovascular, metabolic disease, and infectious diseases. For the type of modality, the firm is open to companies developing small molecule, gene therapy, biologics, and cell therapy.
The firm is interested in privately held life science companies with experienced management teams and innovative technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply